endo_sctoc.htm

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
 
SCHEDULE TO
Tender Offer Statement under Section 14(d)(1) or 13(e)(1)
of the Securities Exchange Act of 1934
 
 
 

PENWEST PHARMACEUTICALS CO.
(Name of Subject Company)

WEST ACQUISITION CORP.
a wholly owned subsidiary of

ENDO PHARMACEUTICALS HOLDINGS INC.
(Name of Filing Person)
 
 
 
 
Common Stock, par value $0.001 per share
(Title of Class of Securities)
 
 
 
 
709754105
(CUSIP Number of Class of Securities)
 
 

Caroline B. Manogue
Executive Vice President, Chief Legal Officer and Secretary
Endo Pharmaceuticals Holdings Inc.
100 Endo Boulevard
Chadds Ford, Pennsylvania 19317
(610) 558-9800
(Name, Address and Telephone Numbers of Person Authorized
to Receive Notices and Communications on Behalf of Filing Persons)
Copy to:
Eileen T. Nugent, Esq.
Ann Beth Stebbins, Esq.
Skadden, Arps, Slate, Meagher & Flom LLP
4 Times Square
New York, New York 10036
(212) 735-3000
 
CALCULATION OF FILING FEE
 
Transaction Valuation
  
Amount of Filing Fee
Not applicable
  
Not applicable
_______
o
Check the box if any part of the fee is offset as provided by Rule 0-11 (a) (2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
     
Amount Previously Paid: None
  
Filing Party: Not applicable
Form or Registration No.: Not applicable
  
Date Filed: Not applicable
■
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
Check the appropriate boxes below to designate any transactions to which the statement relates:
 
■
third-party tender offer subject to Rule 14d-1.
o
issuer tender offer subject to Rule 13e-4.
o
going-private transaction subject to Rule 13e-3.
o
amendment to Schedule 13D under Rule 13d-2.
Check the following box if the filing is a final amendment reporting the results of the tender offer:     o

 
ITEM 12.
EXHIBITS.
   
99.1 Slide Presentation of Endo Pharmaceuticals Holdings Inc., dated August 12, 2010